Express News | Wanfu Biotech: Respiratory triple household self-test OTC products were approved by the US FDA EUA
Express News | Northeast Pharmaceutical: Sun Company obtained registration certificate for injectable azithromycin
Haizheng Pharmaceutical: “Haizheng Dingzhan” can choose to resell
Zhejiang Haizheng Pharmaceutical Co., Ltd. announced that the closing price of the company's stock for 30 consecutive trading days from March 18, 2024 to April 30, 2024 was lower than 80% of the current share conversion price of the company's “Haizheng Transfer”. According to the agreement in the “Transaction Report”, the “Haizheng Ding Transfer” resale clause came into effect.
Shanghai Pharmaceutical (601607): Steady growth in performance is optimistic about improving operations throughout the year
Core view On April 26, the company released the first quarter results report of 2024, achieving operating income of 70.153 billion yuan, an increase of 5.93% over the previous year, and a net profit of 1,542 billion yuan, an increase of 1.6 billion yuan over the previous year
Eling Pharmaceutical (002603): The R&D pipeline is rich and non-respiratory products are growing steadily
Incident: Eling Pharmaceutical released its 2023 annual report and 2024 quarterly report. In 2023, the company achieved revenue of 10.318 billion yuan (-17.67% year-on-year) and net profit of 1,352 billion yuan (year-on-year -42)
Estimating The Intrinsic Value Of Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161)
Key Insights The projected fair value for Beijing Tiantan Biological Products is CN¥25.62 based on 2 Stage Free Cash Flow to Equity With CN¥28.77 share price, Beijing Tiantan Biological Products app